author-photo

Christoph Heuck

Janssen Pharmaceutica

22

Papers

163

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.

2021 ClinicoEconomics and Outcomes Research
Show All
- Source
- Cite
- Save
Citations (0)
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

2021 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (1)
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

2021 Advances in Therapy
Show All
- Source
- Cite
- Save
Citations (2)
Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (30)
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

2020 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias

2019 Blood Advances
Show All
- Source
- Cite
- Save
Citations (3)
RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA: S823

2019 Blood
Show All
- Source
- Cite
- Save
Citations (14)